Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shreyaskumar Patel

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Lancet (London, England)|March 24, 2009
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialRonald P Dematteo, Karla V Ballman, Cristina R Antonescu, et al.
Scientific Reports|October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesVivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Cancers|May 11, 2024
Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal TumorsRyan A Denu, Cissimol P Joseph, Elizabeth S Urquiola, et al.
Sarcoma|June 23, 2020
PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated LiposarcomaAmanda Parkes, Elizabeth Urquiola, Priya Bhosale, et al.
Global Spine Journal|March 28, 2025
AO Spine Clinical Practice Recommendations: Current Systemic Oncological Treatments with the Largest Impact on Patients with Metastatic Spinal DiseaseMarcin Czyz, Emerens G Wensink, Brian Coimbra, et al.
Cancer|April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomasRobin L Jones, Sant P Chawla, Steven Attia, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2022
Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent ChordomaAndrew J Bishop, Behrang Amini, Heather Lin, et al.
Cancer|June 8, 2019
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcomaShreyaskumar Patel, Margaret von Mehren, Damon R Reed, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Lancet (London, England)|March 24, 2009
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialRonald P Dematteo, Karla V Ballman, Cristina R Antonescu, et al.
Scientific Reports|October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesVivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Cancers|May 11, 2024
Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal TumorsRyan A Denu, Cissimol P Joseph, Elizabeth S Urquiola, et al.
Sarcoma|June 23, 2020
PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated LiposarcomaAmanda Parkes, Elizabeth Urquiola, Priya Bhosale, et al.
Global Spine Journal|March 28, 2025
AO Spine Clinical Practice Recommendations: Current Systemic Oncological Treatments with the Largest Impact on Patients with Metastatic Spinal DiseaseMarcin Czyz, Emerens G Wensink, Brian Coimbra, et al.
Cancer|April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomasRobin L Jones, Sant P Chawla, Steven Attia, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2022
Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent ChordomaAndrew J Bishop, Behrang Amini, Heather Lin, et al.
Cancer|June 8, 2019
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcomaShreyaskumar Patel, Margaret von Mehren, Damon R Reed, et al.
Pageof 12